Novo Nordisk A/S (ADR) (NYSE:NVO) fell -0.81% during previous trade. Morgan Stanley issued rating on the stock of Novo Nordisk A/S (ADR) (NYSE:NVO) in a research note issued to investors on Sep-01-16, the stock received “Downgrade” rating from Overweight to Equal-Weight     . Additionally HSBC Securities issued their Verdict on the stock of the company, on record date of Aug-31-16 the stock was “Upgraded” from Reduce to Hold besides that on Aug-08-16 Novo Nordisk A/S (ADR) (NYSE:NVO) was “Downgraded” by BofA/Merrill from Buy to Neutral. Furthermore on Aug-28-15 the stock was “Initiated” by Leerink Partners as Mkt Perform from $56.

Novo Nordisk A/S (ADR) (NYSE:NVO) shares ended last trading session at the price of $46.34 whereas a number of traders indicating mean target price will hit $57.00 over the next twelve months, mean value of price target most recently revised on 08/16/16. Novo Nordisk A/S (ADR) (NYSE:NVO)’s highest estimates of price target are $57.00 and low forecast is $57.00 based on the opinion of 1 analysts. The price target estimates represents a standard deviation of 0.00. However brokerage recommendations suggests an ABR of 3.00 based on calls of 3 experts, where 0 brokers polls the stock a Strong Buy, 0 suggest the stock a Buy, 3 suggest Hold, 0 are rating the stock as Sell while 0 as Strong Sell.

Novo Nordisk A/S (ADR) (NYSE:NVO) is expected to release the earnings of its current quarter on 11/3/16. The company is expected to release $0.58 EPS for current quarter according to 1 analysts whereas the company reported $0.49 EPS during same quarter a year ago. For the current quarter the stock has a lowest EPS estimates of $0.58 and high estimate of $0.58. For the current year Novo Nordisk A/S (ADR) (NYSE:NVO) has set to release EPS of $2.29 as per the sentiments of 2 analysts, however according to 2 analysts, the company expected to release $2.44 EPS for next year.

Novo Nordisk A/S (ADR) (NYSE:NVO)’s average revenue estimates for the current quarter are $4.22B according to 1 number of analysts. However its lowest revenue estimates are $4.22B and highest revenue estimates are $4.22B. A year ago the company’s sales were $3.99B. Its yearly sales growth estimates are 5.80%. For the next quarter the company has anticipated average revenues of $4.39B, according to the sentiments of 1 analysts. For the current year the company has fixed $16.83B revenues, as per the opinion of 2 analysts. For the current year the company has low revenue estimates of $16.75B in contradiction of high revenue estimates of $16.9B. Whereas for the next year revenues are set at $17.59B by 2 analysts.

The stock exchanged hands 2.80M shares versus average trading capacity of 2.85M shares, while its shares’ total market worth is $92.62B along with 1.96B outstanding shares. Novo Nordisk A/S (ADR) (NYSE:NVO) shares were trading -19.30% below from the 52-week high price mark of $57.43 and +3.12% above from the 52-week price bottom of $44.94. However the company observed 52 week high price on 12/30/15 and witnessed 52 week low price on 08/12/16. The company’s price sits 9.98% below from its 50-day moving average of $50.95 and -12.78% away from the stock’s 200-day moving average which is $53.59. Novo Nordisk A/S (ADR) (NYSE:NVO)’s price to sales ratio for trailing twelve month stands at 5.61, whereas its price to book ratio for most recent quarter sits at 18.24. However the company’s price to cash per share for most recent quarter stands at 40.67. Its price to free cash flow for trailing twelve months is 30.06.